Literature DB >> 8706771

Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells.

R Kravtzoff1, I Desbois, J P Lamagnere, J P Muh, C Valat, M Chassaigne, P Colombat, C Ropars.   

Abstract

To evaluate the modification of pharmacodynamic parameters induced by the administration of L-asparaginase loaded into red blood cells, 13 patients received a single dose of L-asparaginase internalised into the carrier. The enzyme was loaded using a reversible lysis-resealing process. The dose per patient ranged from 30 to 200 i.u. kg-1. Considerable heterogeneity occurred between patients. the level of L-asparaginase circulating after 24 h represented 47% of the total injected dose as compared to 74.8% for red blood cells (RBCs). However, the half-life of the enzyme remaining in the circulation was very similar to that of the RBC carrier, i.e. 29 days and 27 days, respectively, compared with 8-24 h for the free enzyme. Sustained elimination of plasma L-asparagine occurred, the duration of which was dependent on the injected dose. A single injection of 30.i.u.kg-1 was sufficient to eliminate plasma L-asparagine over 10 days. With 150-200 IU.kg-1 the elimination period was extended to 50 days. These data show that the use of RBCs as carriers of L-asparaginase greatly improves the pharmacodynamic parameters of the drug.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706771     DOI: 10.1007/BF00195932

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Toxicity of E. coli L-asparaginase in man.

Authors:  H F Oettgen; P A Stephenson; M K Schwartz; R D Leeper; L Tallai; C C Tan; B D Clarkson; R B Golbey; I H Krakoff; D A Karnofsky; M L Murphy; J H Burchenal
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

2.  Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes.

Authors:  H O Alpar; D A Lewis
Journal:  Biochem Pharmacol       Date:  1985-01-15       Impact factor: 5.858

3.  Entrapment of L-asparaginase in red blood cells. A strategy to improve treatment of acute lymphoblastic leukemia.

Authors:  S J Updike
Journal:  Bibl Haematol       Date:  1985

4.  L-Asparaginase as a single agent in acute lymphocytic leukemia: survey of studies form Childrens Cancer Study Group.

Authors:  M E Nesbit; I Ertel; G D Hammond
Journal:  Cancer Treat Rep       Date:  1981

5.  A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma.

Authors:  H B Muss; N Spell; D Scudiery; R L Capizzi; M R Cooper; J Cruz; D V Jackson; F Richards; C L Spurr; D R White
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

6.  Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement.

Authors:  N K Cheung; I Y Chau; P F Coccia
Journal:  Am J Pediatr Hematol Oncol       Date:  1986

7.  Erythrocytes as carriers for L-asparaginase. Methodological and mouse in-vivo studies.

Authors:  R Kravtzoff; C Ropars; M Laguerre; J P Muh; M Chassaigne
Journal:  J Pharm Pharmacol       Date:  1990-07       Impact factor: 3.765

8.  A single-column amino acid analysis method which resolves hexosamines and several cysteine derivatives.

Authors:  M Fauconnet; J Rochemont
Journal:  Anal Biochem       Date:  1978-12       Impact factor: 3.365

9.  Density gradient separation of L-asparaginase-loaded human erythrocytes.

Authors:  M I Garín; R Kravtzoff; N Chestier; S Sanz; M Pinilla; J Luque; C Ropars
Journal:  Biochem Mol Biol Int       Date:  1994-07

10.  Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma.

Authors:  W E Evans; A Tsiatis; G Rivera; S B Murphy; G V Dahl; M Denison; W R Crom; L F Barker; A M Mauer
Journal:  Cancer       Date:  1982-04-01       Impact factor: 6.860

View more
  17 in total

Review 1.  Drug delivery by red blood cells: vascular carriers designed by mother nature.

Authors:  Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

Review 2.  Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.

Authors:  Xavier Thomas; Caroline Le Jeune
Journal:  Int J Hematol Oncol       Date:  2016-05-05

Review 3.  Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond.

Authors:  Carlos H Villa; Douglas B Cines; Don L Siegel; Vladimir Muzykantov
Journal:  Transfus Med Rev       Date:  2016-08-17

Review 4.  Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.

Authors:  Patrick M Glassman; Elizabeth D Hood; Laura T Ferguson; Zongmin Zhao; Don L Siegel; Samir Mitragotri; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2021-09-29       Impact factor: 15.470

Review 5.  Nanotechnology-based cell-mediated delivery systems for cancer therapy and diagnosis.

Authors:  Vahid Alimardani; Zahra Rahiminezhad; Mahvash DehghanKhold; Ghazal Farahavar; Mahboobeh Jafari; Mehdi Abedi; Leila Moradi; Uranous Niroumand; Mohammad Ashfaq; Samira Sadat Abolmaali; Gholamhossein Yousefi
Journal:  Drug Deliv Transl Res       Date:  2022-09-08       Impact factor: 5.671

6.  L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL).

Authors:  Young Min Kwon; Hee Sun Chung; Cheol Moon; James Yockman; Yoon Jeong Park; Scott D Gitlin; Allan E David; Victor C Yang
Journal:  J Control Release       Date:  2009-07-03       Impact factor: 9.776

Review 7.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07

Review 8.  Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.

Authors:  Carlos H Villa; Aaron C Anselmo; Samir Mitragotri; Vladimir Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2016-03-03       Impact factor: 15.470

Review 9.  Co-opting biology to deliver drugs.

Authors:  Parisa Yousefpour; Ashutosh Chilkoti
Journal:  Biotechnol Bioeng       Date:  2014-07-21       Impact factor: 4.530

10.  Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment.

Authors:  Cristina Díaz-Barriga; Francisca Villanueva-Flores; Katrin Quester; Andrés Zárate-Romero; Ruben Dario Cadena-Nava; Alejandro Huerta-Saquero
Journal:  Pharmaceutics       Date:  2021-04-22       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.